FDA OKs new J& J treatment for psoriasis

TRENTON, N.J. — U.S. regulators approved a new psoriasis drug from Johnson & Johnson Thursday. Johnson & Johnson said that in one patient study, about seven in 10 patients getting the drug, Tremfya, had clear or nearly clear skin after 24 weeks of treatment. That compares with about four in 10 patients receiving rival AbbVie’s Humira, which treats several immune disorders and is the world’s top selling drug.